Combination of Astrogliosis and Phosphorylated Tau for the Preclinical Diagnosis of Alzheimer Disease Using 3-Dimensional Stereotactic Surface Projection Images With 18 F-THK5351

Clin Nucl Med. 2022 Dec 1;47(12):1066-1068. doi: 10.1097/RLU.0000000000004425. Epub 2022 Sep 30.

Abstract

The Alzheimer disease (AD) brain is characterized microscopically by the presence of extracellular amyloid plaques and intraneuronal neurofibrillary tangles consisting of phosphorylated tau aggregations. 18 F-THK5351 is a first-generation PET tau tracer that also binds to monoamine oxidase B, which represents astrogliosis, and is useful to evaluate some non-AD neurodegenerative disorders. We examined the utility of 18 F-THK5351 in preclinical AD using 3-dimensional stereotactic surface projection images optimized for its pathological accumulation by comparison with a normal dataset. By using this 18 F-THK5351 3-dimensional stereotactic surface projection procedure, which can evaluate phosphorylated tau and neuroinflammation, we could diagnose preclinical AD effectively.

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Alzheimer Disease* / metabolism
  • Brain / diagnostic imaging
  • Brain / metabolism
  • Gliosis / diagnostic imaging
  • Gliosis / metabolism
  • Humans
  • Positron-Emission Tomography / methods
  • tau Proteins / metabolism

Substances

  • THK5351
  • tau Proteins